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Background: Among older persons, we previously endorsed a two-step spirometric definition of
chronic obstructive pulmonary disease (COPD) that requires a ratio of forced expiratory
volume in 1 sec to forced vital capacity (FEV1/FVC) below .70, and an FEV1 below the 5th or
10th standardized residual percentile (‘‘SR-tile strategy’’).
Objective: To evaluate the clinical validity of an SR-tile strategy, compared to a current
definition of COPD, as published by the Global Initiative for Obstructive Lung Disease (GOLD-
COPD), in older persons.
Methods: We assessed national data from 2480 persons aged 65e80 years. In separate
analyses, we evaluated the association of an SR-tile strategy with mortality and respiratory
symptoms, relative to GOLD-COPD. As per convention, GOLD-COPD was defined solely by an
FEV1/FVC< .70, with severity staged according to FEV1 cut-points at 80 and 50 percent pre-
dicted (%Pred).
Results: Among 831 participants with GOLD-COPD, the risk of death was elevated only in 179
(21.5%) of those who also had an FEV1< 5th SR-tile; and the odds of having respiratory symp-
toms were elevated only in 310 (37.4%) of those who also had an FEV1< 10th SR-tile. In
contrast, GOLD-COPD staged at an FEV1 50e79%Pred led to misclassification (overestimation)
in terms of 209 (66.4%) and 77 (24.6%) participants, respectively, not having an increased risk
of death or likelihood of respiratory symptoms.dicine, Clinical Epidemiology Research Center, VA Connecticut Healthcare System, Mailcode 151B,
203 688 9423; fax: þ1 203 688 4209.
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1190 C.A. Vaz Fragoso et al.Conclusion: Relative to an SR-tile strategy, the majority of older persons with GOLD-COPD had
neither an increased risk of death nor an increased likelihood of respiratory symptoms. These
results raise concerns about the clinical validity of GOLD guidelines in older persons.
Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is charac-
terized by airflow limitation, defined spirometrically by
a reduced ratio of forced expiratory volume in 1 sec (FEV1)
to forced vital capacity (FVC), with severity subsequently
staged according to the FEV1 expressed as percent
predicted (%Pred).1e4 In particular, the Global initiative for
Obstructive Lung Disease (GOLD), a frequently cited spiro-
metric guideline, establishes COPD based solely on an FEV1/
FVC< .70, with severity subsequently staged according to
FEV1 cut-points of 80, 50, and 30%Pred.
1
Among older persons, GOLD guidelines are problematic,
however, for at least three reasons. First, an FEV1/FVC
threshold of .70 cannot distinguish clinically-significant
pathology from normal age-related increases in airflow
limitation.2,5 Developmentally, after achieving peak
pulmonary function at about 20 years of age, airflow limi-
tation increases with age, principally due to increasing
rigidity of the chest wall and decreasing elastic recoil of the
lung.6,7 Although COPD is also characterized by airflow
limitation, this effect is due to small airways disease and
parenchymal destruction.1,8 Consequently, an FEV1/
FVC< .70 may simply reflect airflow limitation that is due
to normal aging, rather than COPD.2,5 Second, GOLD
assumes incorrectly that a given FEV1%Pred cut-point is
equivalent for all persons regardless of age, height, sex and
ethnicity.9e11 For example, a white male of average height
has a value for the FEV1 at the 5th percentile of 74%Pred at
age 30 years, but only 63%Pred at age 70 years.9 Third,
GOLD guidelines have not been validated using clinically
relevant measures such as mortality and respiratory symp-
toms.1 Because of these limitations, GOLD may misclassify
COPD in older persons and, in turn, potentially compromise
patient care.2,3,5,9e13
To address the above limitations, we have proposed
that COPD be defined by a two-step spirometric strategy
that 1) determines a cut-point for the FEV1/FVC based on
mortality risk; and 2) among persons below this FEV1/FVC
threshold, determines cut-points for the FEV1, expressed
as a standardized residual percentile (SR-tile) and based
on the prevalence of respiratory symptoms and mortality
risk.11 An SR-tile is simply a Z-score that has been con-
verted to a percentile,9e11 and is analogous to results
reported for bone mineral density testing.14 Importantly,
the SR-tile method accounts for variability in age, height,
sex, and ethnicity, whereas %Pred does not.9e11 Using this
approach and data from the Third National Health and
Nutrition Examination Survey (NHANES III), we have shown
that, among persons aged 65e80 years, defining COPD
based on an FEV1/FVC< .70, with FEV1 cut-points at the
5th and 10th SR-tile, identifies individuals with an
increased risk of death and prevalence of respiratory
symptoms, respectively.11In the current study, we evaluated the clinical validity of
an SR-tile based strategy, relative to GOLD-defined COPD,
using data from a large, nationally representative sample of
community-living older persons, which included a large
proportion of women and minorities. We postulated that
GOLD guidelines would misclassify older persons who have
neither an increased risk of death nor an increased preva-
lence of respiratory symptoms.
Methods
Study population
NHANES III is a large, nationally representative sample of
Americans assembled in 1988e1994, with mortality
surveillance through December 31, 2000.15,16 Our study
population included 2480 community-living NHANES III
participants, aged 65e80 years, who were white, African-
American, or Mexican-American, had no self-reported
asthma, and had completed a health questionnaire,
a brief cognitive assessment, and at least two American
Thoracic Society (ATS) acceptable spirometric maneu-
vers.17 As per current ATS recommendations, we did not
exclude participants based on spirometric reproducibility
criteria.18
The Yale Human Investigation Committee approved the
study, granting exemption from review and subject consent
because it involved existing data that was publicly available
and recorded in a manner that subjects could not be
identified.
Clinical measures
Participants were classified as having a respiratory
symptom if they answered ‘‘yes’’ to one or more of the
following four questions: ‘‘Do you usually cough on most
days for 3 consecutive months or more during the year?’’,
‘‘Do you bring up phlegm on most days for 3 consecutive
months or more during the year?’’, ‘‘Have you had
wheezing or whistling in your chest at any time in the
past 12 months?’’, or ‘‘Are you troubled by shortness of
breath when hurrying on level ground or walking up
a slight hill?’’.
Self-reported asthma was defined by a ‘‘yes’’ response
to: ‘‘Has a doctor ever told you that you had asthma?’’ Self-
reported COPD was defined by a ‘‘yes’’ response to: ‘‘Has
a doctor ever told you that you had chronic bronchitis?’’ or
‘‘Has a doctor ever told you that you had emphysema?’’
Current smokers were defined by a ‘‘yes’’ response to: ‘‘Do
you smoke cigarettes now?’’ Former smokers were defined
by a ‘‘no’’ response to: ‘‘Do you smoke cigarettes now?’’
but a ‘‘yes’’ response to: ‘‘Have you smoked at least 100
cigarettes during your entire life?’’ Never smokers were
defined by ‘‘no’’ responses to both questions.
Table 1 Baseline characteristics of the study population.
Characteristic NZ 2480
Age, mean (SD), years 71.7 (4.5)
Females, No. (%) 1252 (50.5)
Ethnicity, No. (%)
White 1497 (60.4)
African-American 517 (20.8)
Mexican-American 466 (18.8)
Education, mean (SD), years 9.7 (4.4)
Smoking status, No. (%)
Never 1108 (44.7)
Former 1001 (40.4)
Current 371 (15.0)
Self-reported chronic conditions, No. (%)
Hypertension 1194 (48.3)
Arthritis 1107 (44.6)
Diabetes mellitus 407 (16.4)
Myocardial infarction 272 (11.1)
Chronic obstructive pulmonary disease 214 (8.6)
Congestive heart failure 205 (8.3)
Cancera 199 (8.0)
Stroke 173 (7.0)
Fair-to-poor self-reported health, No. (%) 824 (33.3)
Memory impairment, No. (%)b 859 (34.9)
SDZ standard deviation; FEV1Z forced expiratory volume in
1 sec; FVCZ forced vital capacity; %PredZ percent predicted;
LLNZ lower limit of normal.
a Minor skin cancers are not included.
b A score <2 on delayed recall of a 3-item word list or
a score< 4 on delayed recall from a 6-item story.
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‘‘Would you say your health in general is excellent, very
good, good, fair, or poor?’’ Reduced health status was
defined as a rating of ‘‘fair-to-poor.’’ To assess comorbid-
ity, participants were asked about the presence of several
chronic conditions in addition to COPD, including hyper-
tension, diabetes, congestive heart failure, stroke,
myocardial infarction, and lung cancer. Body mass index
(BMI) was defined as a ratio of the measured weight in
kilograms to measured height in meters-squared. Finally,
memory impairment was defined as a score <2 on delayed
recall of a 3-item word list or a score <4 on delayed recall
from a 6-item story.15
Spirometry
NHANES III utilized a dry rolling seal spirometer, with each
participant performing 5e8 forced vital capacity (FVC)
maneuvers.15 For predicted values, we used previously
published NHANES III reference equations based on age,
height, sex, and ethnicity.11 As described earlier, an FEV1/
FVC threshold of .70 defined COPD with GOLD guidelines
(i.e., GOLD-COPD),1 but was considered only a first step in
an SR-tile based definition of COPD.11
As proposed by GOLD, we expressed the measured FEV1
as %Pred, calculated as (measuredO predicted) 100.1
Among participants with GOLD-COPD, we then staged the
FEV1 at 80, 50, and 30%Pred.
1 However, because only a small
number of NHANES III participants had an FEV1< 30%Pred
(nZ 10), we subsequently used only the cut-points of 80
and 50%Pred to define three GOLD-COPD stages: Stage 1
(FEV1 80%Pred), Stage 2 (FEV1 50e79%Pred), and
(combined) Stage 3/4 (FEV1< 50%Pred).
As per the SR-tile strategy,11 we expressed the measured
FEV1 as a standardized residual (SR), calculated as
[(measured minus predicted)/(standard deviation of the
residuals)].9e11 A ‘‘residual’’ is the difference between
a measured and predicted value, and the standard deviation
of the residuals is a constant that quantifies the spread of
the reference data, based on age, height, sex, and ethnicity
(i.e., derived from reference equations for the FEV1).
9e11
A percentile based on the SR was then computed (SR-tile),
with an easy-to-interpret scale of 0e100.9e11 Among
participants with an FEV1/FVC< .70, we then established
COPD based on the FEV1, using previously validated cut-
points at the 5th and 10th SR-tiles, respectively.11
Lastly, for our regression analyses (described below), we
excluded persons with restrictive lung disease from the
referent group (FEV1/FVC .70), based on an FVC< LLN.19
Primary outcome
Our primary outcome was all-cause mortality, ascertained
from a public-use linked mortality file that contains infor-
mation from the National Death Index, with follow-up
through December 31, 2000.16 Vital status was available
on all but one participant.16
Statistical analysis
SUDAAN version 9.0.1 (Research Triangle Park) was used to
estimate hazard ratios (from Cox proportional hazardsregression) and odds ratios (from logistic regression), with
a p< .05 (two-sided) denoting statistical significance.20
Among participants with an FEV1/FVC< .70, we deter-
mined the independent association between FEV1 stage and
death, using Cox proportional hazards analysis. Models
were adjusted for age, height, sex, ethnicity, smoking
history, chronic conditions, health status, BMI, and cogni-
tion. The proportional hazards assumption was tested using
interaction terms crossing the time-to-event outcome with
each variable in the multivariable model. If significant at
the p< .05 level, these interaction terms were retained in
the final model. Higher order effects were tested for the
continuous covariates and were included in the final models
if they met the forward selection criterion of p< .20.21
Participants who had not died were censored at the end
of the follow-up period.
The FEV1 stages were based, in separate analyses, on an
FEV1 at the 5th SR-tile or GOLD cut-points. The groups
demarcated by these cut-points were treated as nominal
categories, with the referent group including participants
having normal pulmonary function, defined by an FEV1/
FVC .70 and an FVC LLN.19 Mortality risk was subse-
quently evaluated for GOLD stages stratified by FEV1 at the
5th SR-tile. Similarly, among participants with an FEV1/
FVC< .70, we also evaluated the association between
GOLD stages stratified by an FEV1 at the 10th SR-tile and the
presence of respiratory symptoms, by calculating odds
Table 2 All-cause mortality and prevalence of respiratory symptoms, according to GOLD and SR-tile cut-points.
A. All-cause mortality:
Spirometric group No. (%) of deaths among participantsa
Normal pulmonary functionb 429/1488 (28.8)
FEV1/FVC< .70: FEV1 stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
5th SR-tile 163/443 (36.8) 90/209 (43.1) 0 253/652 (38.8)
<5th SR-tile 0 55/105 (52.4) 56/74 (75.7) 111/179 (62.0)
Total 163/443 (36.8) 145/314 (46.2) 56/74 (75.7) 364/831 (43.8)
B. Respiratory symptomsc:
Spirometric group No. (%) of participants with respiratory symptomsd
Normal pulmonary functionb 614/1483 (41.4)
FEV1/FVC< .70: FEV1 Stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
10th SR-tile 172/442 (38.9) 40/77 (52.0) 0 212/519 (40.8)
<10th SR-tile 1/1 (100) 141/236 (59.8) 59/74 (79.7) 201/311 (64.6)
Total 173/443 (39.0) 181/313 (57.8) 59/74 (79.7) 413/830 (49.8)
COPDZ chronic obstructive pulmonary disease; FEV1Z forced expiratory volume in 1 sec; FVCZ forced vital capacity; %PredZ percent
predicted; SR-tileZ standardized residual percentile; GOLDZGlobal Initiative for Obstructive Lung Disease; LLNZ lower limit of
normal.
a 74 Participants (3.6%) were excluded because of missing covariates and 87 (3.5%) were excluded because of restrictive pulmonary
physiology, i.e., FEV1/FVC .70 and FVC< LLN.
b Defined by an FEV1/FVC .70 and FVC LLN.
c Included cough or sputum production, wheezing, or exertional dyspnea e see Methods.
d 80 Participants (3.2%) were excluded because of missing covariates or missing respiratory symptoms (nZ 6), and 87 (3.5%) were
excluded because of restrictive pulmonary physiology, i.e., FEV1/FVC .70 and FVC< LLN.
1192 C.A. Vaz Fragoso et al.ratios using logistic regression. Respiratory symptoms were
evaluated as a composite measure but, to enhance the
interpretation of our findings, we also evaluated the
symptoms of dyspnea, wheezing, and ‘‘bronchitis’’ (i.e.,
cough or sputum production) separately.
Results
The baseline characteristics of our study population are
shown in Table 1. The mean age was approximately 72
years. The majority of participants were current or former
smokers. The five most common self-reported chronic
conditions were hypertension, arthritis, diabetes mellitus,
myocardial infarction, and COPD. About a third of the
participants had fair-to-poor health status and memory
impairment, respectively. Over the 12-year follow-up
period, 868 (35.0%) participants died, yielding a mortality
rate of 4.6 per 100 person-years (95% confidence interval
4.3, 4.9).
Table 2 provides all-cause mortality and the preva-
lence of respiratory symptoms among participants with
normal pulmonary function versus those with an FEV1/
FVC< .70, stratified according to the FEV1 as defined by
GOLD and SR-tile cut-points. As shown in Panel A, the
highest mortality occurred among participants who had
an FEV1< 50%Pred and <5th SR-tile. As shown in Panel B,
the highest prevalence of respiratory symptoms occurred
among participants who had an FEV1< 50%Pred and <10th
SR-tile.
Table 3 provides unadjusted and adjusted hazard ratios
(HR) for all-cause mortality among participants with an
FEV1/FVC< .70, stratified according to GOLD and SR-tilecut-points, relative to a reference group with normal
pulmonary function. As shown in Panel A, the unadjusted
HR was significantly elevated among participants with an
FEV1/FVC< .70, regardless of FEV1 cut-point. After
adjustment for potential confounders, however, as shown
in Panel B, the adjusted HR was significantly elevated only
at an FEV1< 5th SR-tile, regardless of GOLD staging.
Consequently, of the 831 participants who had GOLD-COPD
(FEV1/FVC< .70), the risk of death was elevated only in 179
(21.5%) of those who also had an FEV1< 5th SR-tile; and, of
the 314 participants with GOLD-COPD Stage 2 (FEV1 50e
79%Pred), the risk of death was misclassified in 209 (66%) of
those who also had an FEV1 5th SR-tile.
Table 4 provides unadjusted and adjusted odds ratios
(OR) for having respiratory symptoms among participants
with an FEV1/FVC< .70, stratified to GOLD and SR-tile cut-
points, relative to a reference group with normal pulmo-
nary function. As shown in Panel A, the unadjusted odds
ratios were significantly elevated among participants with
an FEV1/FVC< .70, regardless of FEV1 cut-point. After
adjustment for potential confounders, however, as shown
in Panel B, the adjusted OR was significantly elevated only
at an FEV1< 10th SR-tile, regardless of GOLD staging.
Consequently, of the 829 participants who had GOLD-COPD
(FEV1/FVC< .70), the odds of having respiratory symptoms
was elevated only in 310 (37.4%) of those who also had an
FEV1< 10th SR-tile; and, of the 313 participants with GOLD-
COPD Stage 2 (FEV1 50e79%Pred), the likelihood of having
respiratory symptoms was misclassified in 77 (24.6%) of
those who also had an FEV1 10th SR-tile. Similar results
were obtained when each of the respiratory symptoms was
analyzed separately (data not shown).
Table 3 Unadjusted and adjusted hazard ratios for all-cause mortality, according to GOLD and SR-tile cut-points.a
A. Unadjusted hazard ratios:
Spirometric group Unadjusted hazard ratio (95% CI) for mortality
Normal pulmonary functionb 1.00
FEV1/FVC< .70: FEV1 Stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
5th SR-tile 1.25 (1.04, 1.50) 1.59 (1.29, 1.96) NA 1.35 (1.14, 1.61)
<5th SR-tile NA 2.27 (1.83, 2.81) 3.94 (3.08, 5.03) 2.85 (2.36, 3.45)
Total 1.25 (1.04, 1.50) 1.81 (1.51, 2.16) 3.93 (3.08,5.02) 1.62 (1.37, 1.91)
B. Adjusted hazard ratios:
Spirometric group Adjusted hazard ratio (95% CI) for mortalityc
Normal pulmonary functionb 1.00
FEV1/FVC< .70: FEV1 Stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
5th SR-tile 1.03 (0.85, 1.26)
nZ 443
1.11 (0.91, 1.36)
nZ 209
NA
nZ 0
1.06 (0.89, 1.25)
nZ 652
<5th SR-tile NA
nZ 0
1.83 (1.41, 2.37)
nZ 105
2.24 (1.65, 3.04)
nZ 74
2.01 (1.60, 2.54)
nZ 179
Total 1.04 (0.85, 1.27)
nZ 443
1.31 (1.08, 1.59)
nZ 314
2.24 (1.65, 3.03)
nZ 74
1.24 (1.04, 1.47)
nZ 831
COPDZ chronic obstructive pulmonary disease; FEV1Z forced expiratory volume in 1 sec; FVCZ forced vital capacity; %PredZ percent
predicted; SR-tileZ standardized residual percentile; GOLDZGlobal Initiative for Obstructive Lung Disease; LLNZ lower limit of
normal; CIZ confidence interval; NAZ not applicable.
a 74 Participants (3.6%) were excluded because of missing covariates and 87 (3.5%) were excluded because of restrictive pulmonary
physiology, i.e., FEV1/FVC .70 and FVC< LLN.
b Defined by an FEV1/FVC .70 and FVC LLN.
c Covariates included age, age2, height, sex, ethnicity, smoking history, BMI, BMI2, BMI3, memory impairment, self-reported health
status by time interaction, and chronic conditions. All covariates were significant at the p .05 level, except age2 at a p value of .196
but this was kept in the model because we used the .20 level for higher order terms.
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In a large, nationally representative sample of community-
living older persons, the majority of participants with
GOLD-defined COPD had neither an increased risk of death
(78.5%) nor an increased prevalence of respiratory
symptoms (62.5%), relative to a two-step, SR-tile based
spirometric definition of COPD. In addition, the risk of
death and likelihood of having respiratory symptoms were
misclassified in 209 (66.4%) and 77 (24.6%) participants,
respectively, who had GOLD-COPD Stage 2 (FEV1 50e
79%Pred). These results raise concerns about the clinical
validity of GOLD guidelines in older persons.
Our two-step, SR-tile based spirometric strategy for
defining COPD in older persons offers three major advan-
tages over GOLD guidelines. First, unlike GOLD, we have
previously established spirometric cut-points that are
associated with important clinical measures.11 All-cause
mortality is an objective and definitive health outcome
that is resistant to miscoding and has been the primary
endpoint in landmark studies of oxygen therapy in COPD.22
In addition, respiratory symptoms are the most distressing
feature of COPD and can lead to disability and increased
healthcare utilization.22,23
Second, we have evaluated the FEV1 as an SR-tile rather
than as %Pred, which is the practice espoused by GOLD and
others.1e4 Prior work has shown that reporting the FEV1 as
%Pred is seriously flawed, because it does not account fordifferences in the variability of the reference group across
the lifespan.9e11 In contrast, because it considers the
spread of the reference data, the SR-tile method yields
a value that is applicable to all persons.9,10
Third, contrary to GOLD, our spirometric strategy posits
that the FEV1/FVC, when expressed as a fixed ratio, is
insufficient to establish a diagnosis of COPD. As discussed
earlier, an FEV1/FVC threshold at a ratio of .70 cannot
distinguish clinically-significant pathology from normal age-
related increases in airflow limitation.2,5 To better make
this distinction, it is necessary to also consider the FEV1,
because it is the primary determinant of a reduced FEV1/
FVC, is a more robust predictor of adverse outcomes (than
the FEV1/FVC), and is associated with COPD-related airway
inflammation.2,8,11,24 Nonetheless, the first step in the
diagnostic sequence for establishing COPD still requires the
FEV1/FVC, because a reduced FEV1 may be also due to
restrictive lung physiology.1,2,11
Using our spirometric strategy and data from NHANES III,
we have previously shown that 7.7% of persons aged 65e80
years had a severe form of COPD, defined by an FEV1/
FVC< .70 and an FEV1< 5th SR-tile, which conferred an
increased risk of death and an increased prevalence of
respiratory symptoms; this subgroup had the highest preva-
lence of smoking exposure and reduced health status.11
Participants with an FEV1/FVC< .70 and an FEV1 at the 5th
to 9th SR-tile, representing 5.7% of the study population, had
a milder form of COPD, which conferred an increased
Table 4 Unadjusted and adjusted odds ratios for having respiratory symptoms, according to GOLD and SR-tile cut-points.a,b
A. Unadjusted odds ratios:
Spirometric group Unadjusted odds ratio (95% CI) for respiratory symptoms
Normal pulmonary functionc 1.00
FEV1/FVC< .70: FEV1 Stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
10th SR-tile 0.90 (0.75e1.09) 1.53 (0.96e2.45) NA 0.98 (0.82e1.16)
<10th SR-tile NA 2.10 (1.50e2.94) 5.57 (3.13e9.89) 2.57 (1.91e3.48)
Total 0.90 (0.75e1.09) 1.94 (1.43e2.63) 5.57 (3.13e9.89) 1.40 (1.18e1.66)
B. Adjusted odds ratios:
Spirometric group Adjusted odds ratio (95% CI) for respiratory symptomsd
Normal pulmonary functionc 1.00
FEV1/FVC< .70: FEV1 Stage GOLD Stage 1
80%Pred
GOLD Stage 2
50e79%Pred
GOLD Stage 3/4
<50%Pred
Total
10th SR-tile 1.08 (0.88e1.33)
nZ 442
1.41 (0.84e2.38)
nZ 77
NA
nZ 0
1.12 (0.92e1.35)
nZ 519
<10th SR-tile NA
nZ 1
2.06 (1.44e2.93)
nZ 236
5.04 (2.88e8.83)
nZ 74
2.45 (1.80e3.34)
nZ 310
Total 1.08 (0.88e1.33)
nZ 442
1.88 (1.34e2.63)
nZ 313
5.05 (2.88e8.85)
nZ 74
1.48 (1.23e1.80)
nZ 829
FEV1Z forced expiratory volume in 1 sec; FVCZ forced vital capacity; %PredZ percent predicted; SR-tileZ standardized residual
percentile; GOLDZGlobal Initiative for Obstructive Lung Disease; LLNZ lower limit of normal; CIZ confidence interval.
a Respiratory symptoms included cough or sputum production, wheezing, or exertional dyspnea e see Methods.
b 80 Participants (3.2%) were excluded because of missing covariates or missing respiratory symptoms (nZ 6), and 87 (3.5%) were
excluded because of restrictive pulmonary physiology, i.e., FEV1/FVC .70 and FVC< LLN. In addition, we excluded from analysis the
single participant who had an FEV1/FVC< .70, with an FEV1 80%Pred but <10th SR-tile (cell size too small).
c Defined by an FEV1/FVC .70 and FVC LLN.
d Covariates included age, age2, age3, height, sex, ethnicity, smoking history, BMI, memory impairment, self-reported health status,
and chronic conditions. Of these, age2, ethnicity, smoking, BMI, self-reported health status, and chronic conditions were significant at
the p .05 level. The non-significant variables were kept in the model to have a consistent set of predictors, as in the mortality analysis.
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of death; this subgroup had the second highest prevalence of
smoking exposure and reduced health status.11 Because
neither the risk of death nor prevalence of respiratory
symptoms was elevated, we would suggest that an FEV1/
FVC< .70 with an FEV1 10th SR-tile is insufficient to
establish COPD. Although longitudinal studies are needed,
this latter group may be heterogeneous, including persons
who simply have normal age-related increases in airflow
limitation and those who will experience declines in pulmo-
nary function over time (i.e., transition to COPD).25
The ATS and the European Respiratory Society (ERS)
have recommended an alternative strategy for establishing
COPD, based on the lower limit of normal (LLN) for the
FEV1/FVC, defined as the 5th percentile of the frequency
distribution.2 This strategy, however, may not be viable in
older persons. Because aging is associated with an increase
in the variability of pulmonary function, there is substantial
scatter of the reference data, particularly for a ratio of two
different spirometric measures.6,26 Specifically, among
older persons, normal values for the FEV1/FVC range widely
and are highly skewed, in comparison to the FEV1 and FVC
alone.6,26 Consequently, a threshold based on the LLN for
the FEV1/FVC may have limited diagnostic accuracy in an
older population. To illustrate, prior work has shown that
elderly persons with an FEV1/FVC< .70 but LLN have an
increased risk of death and COPD-related hospitalization.19An alternative strategy for calculating the LLN of the
FEV1/FVC, which accounts for the increase in variability of
pulmonary function with advancing age, has been recently
proposed by Stanojevic and colleagues.6,26 Although this
approach offers promise, reference values are currently
available for white persons only and the clinical validity of
this approach has not yet been established in older
persons.6,26 Other investigators have reported that the
BODE Index, which includes dyspnea, body mass index, 6-
min walking distance, and FEV1, is a better predictor of
mortality than the FEV1 alone, in patients with COPD. By
defining COPD based solely on an FEV1/FVC .70 and
expressing the FEV1 as %Pred, however, the BODE Index
suffers from similar limitations as GOLD.
We recognize potential limitations to our study.
Because cause of death in NHANES III was based only on
information from death certificates, we evaluated all-
cause mortality as an outcome rather than COPD-specific
mortality. Prior work has demonstrated that COPD is
commonly underreported as a cause of death, even among
patients with symptomatic COPD.27 Furthermore, COPD
increases the risk of death from cardiovascular disease
and lung cancer, and the number of deaths from these
causes is much greater than those from respiratory disease
among patients with COPD.28e30 Nonetheless, our findings
should be validated in cohorts that include adjudicated
data on cause of death.
Chronic obstructive pulmonary disease in older persons 1195Whether our results are applicable to middle-aged
persons is uncertain, but should be the focus of future
research. The variability of pulmonary function (i.e., the
spread of the reference data) is less pronounced in middle-
aged persons than in older persons,6,26 which may attenuate
the bias introduced by age-related changes on %Pred.
Lastly, because spirometry in NHANES III was not obtained
after a bronchodilator, we could not assess reversibility of
airflow limitation, a recommended criterion for defining
COPD.1,2 It is unlikely, however, that the absence of infor-
mation on ‘‘reversibility’’ had a meaningful effect on our
results, for at least three reasons. First, prior work has
shown that reversibility, when defined by an FEV1/FVC that
normalizes to >.70, is observed in persons who have
a minimally reduced pre-bronchodilator FEV1/FVC (i.e.,
mean value of .68).31 In contrast, our spirometric definition
of mild and severe COPD yielded a mean FEV1/FVC of .60
and .54, respectively.11 Second, reversibility as defined by
the FEV1 response is neither a sufficient criterion to exclude
COPD nor an independent predictor of mortality.32,33 Third,
persons with self-reported asthma were excluded from our
study population. Although asthma may have been under-
reported,34 we would argue that NHANES III participants
who had airflow limitation defined by an FEV1/FVC .70
and an FEV1 cut-points at the 5th and 10th SR-tile, respec-
tively, were much more likely to have had COPD than
asthma given their high prevalence of smoking exposure.
In conclusion, relative to our evidence-based, two-step
spirometric definition of COPD, the majority of older
persons with GOLD-defined COPD had neither an increased
risk of death nor an increased prevalence of respiratory
symptoms. These results raise concerns about the clinical
validity of GOLD guidelines in older persons.
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